NIH funding uncertainty spurs new biotech venture fund
The Trump administration's directive to limit NIH funding could delay or eliminate grants to early-stage biotech startups, despite a federal judge's temporary block.
MAIN POINTS
- The Trump administration aimed to limit NIH funding for certain research.
- A federal judge temporarily blocked the policy change.
- Early-stage biotech startups might face grant delays or eliminations.
- Chris Gibson, a biotech co-founder, highlighted potential funding impacts.
TAKEAWAYS
- Policy changes can significantly impact research funding and timelines.
- Legal interventions can temporarily halt government policy implementations.
- Startups in the biotech sector are vulnerable to funding fluctuations.
- Industry leaders often voice concerns about policy impacts on innovation.